Corteva, Inc.
NYSE: CTVA·Indianapolis, Indiana·CIK 0001755672
- Price
- $9.04
- Base IV
- $14.66
Valuation snapshot
At $9.04, the price sits between our bear case ($5.58) and base case ($14.66).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $14.66
- above today's price · range $5.58–$26.34
- Price vs base case
- 38% below
- $9.04 against $14.66
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 4.1% since this valuation was struck on 2026-11-13, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $5.58 to bull $26.34. Values per share.
Price against each value
- Bear case
- $5.58
- Price 62% above
- No growth
- …
- —
- Base case
- $14.66
- Price 38% below
What does Corteva do?
Corteva provides agricultural products and services that help farmers increase crop yields and protect plants from pests, diseases, and environmental stressors.
It brought in $17.7B of sales in the 12 months to Sep 2026.
Led by Luther "Luke" Kissam, Chief Executive Officer and Director since 2026. Corteva, Inc. Form 8-K (separation completed; officer appointments effective October 1, 2026)
- Industry
- Materials
- Based in
- Indianapolis, Indiana
- Trades on
- NYSE as CTVA
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 4¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 50¢ of every dollar.
- Making what it sells50¢
- Research and development9¢
- Sales, marketing and admin21¢
- Everything else, including interest13¢
- Tax3¢
- Other items after tax1¢
- Left as profit4¢
Who pays Corteva, and for what?
In 2025, Corteva sold seeds and products that protect crops from weeds, insects and disease. It also earned income by licensing seed traits. These figures describe Corteva before its Seed business was spun off in October 2026.
Farmers buy its products directly or through retailers, distributors and agricultural cooperatives; other seed companies pay to license its technology.
Seed
57%Commercial seeds, seed traits and licensing; $9.898 billion of 2025 sales. This business was spun off in October 2026.
Crop Protection
43%Products for weeds, insects, disease and crop health; $7.503 billion of 2025 sales.
Enlist One herbicide container.Image: Farmers Business Network
Where its work physically happens, beyond headquarters:
- Midland Crop Protection site — Midland, United States. A $242 million expansion increased production capacity for spinosyn insecticides sold into more than 100 countries.
- Harbor Beach spinosyn site — Harbor Beach, United States. Its spinosyn production expansion, together with Midland’s, increased Corteva’s capacity for these insecticides by 50%.
- Cernay production site — Cernay, France. Cernay is one of Corteva’s French crop protection production sites and supports formulation and packaging research.
- Drusenheim production site — Drusenheim, France. The site produces crop protection products and has adapted herbicide packaging for European markets.
- Valdosta Manufacturing Center — Valdosta, United States. The operating crop protection plant supplies manufactured products, including fungicide formulations identified in Corteva product documentation.
How is the business doing?
Sales grew from $14.2B in 2020 to $17.4B in 2025, about 4% a year.
It used $149M more cash than it generated in the 12 months to Sep 2026, paid for out of savings or new money.
What does management say it's aiming for?
Corteva says it aims to improve life for farmers and consumers for generations to come.
“To enrich the lives of those who produce and those who consume, ensuring progress for generations to come.”
Who is responsible for the plan?
- Luther "Luke" KissamChief Executive Officer and Director
Leads Corteva, which since separating the Vylor seed business on October 1, 2026 is a stand-alone crop protection company. Corteva now earns its revenue mainly from selling crop protection products such as herbicides, insecticides, fungicides and biologicals.
- Brook CunninghamChief Commercial Officer
Oversees global sales and marketing, commercial excellence, the crop protection and plant health segments, business development and customer engagement. The commercial organization sells Corteva's crop protection and plant health products to growers and distribution channels, which is how the company generates its net sales.
- Reza RasoulpourChief Technology Officer
Leads Corteva's global research and development organization and innovation strategy, including discovery, development, and product safety and stewardship. R&D discovers, develops and gets regulatory approval for the crop protection active ingredients and biologicals that Corteva sells.
Roles checked November 9, 2026.
What management says it is working on now:
Bring new products to farmers
Management says it is focused on seeds and crop protection products that help farmers improve yields and address changing conditions.
Corteva 2025 Form 10-KImprove operations
Management is reducing costs and improving productivity, including by changing its Crop Protection manufacturing network.
Corteva 2025 Form 10-KGrow through licensing
The 2025 plan called for gaining share by licensing more Seed traits to other companies. Seed became a separate company in October 2026.
Corteva 2025 Form 10-K
- Operating EBITDA, Full year 2026; guidance for the combined company given before the October spin-off
- $4.1 billion to $4.3 billion
- Corteva Q2 2026 earnings call transcript
- Operating EBITDA margin, Full year 2026; guidance for the combined company given before the October spin-off
- 22.5% to 23.5%
- Corteva Q2 2026 earnings call transcript
- Operating earnings per share, Full year 2026; guidance for the combined company given before the October spin-off
- $3.60 to $3.80
- Corteva Q2 2026 earnings call transcript
What's changing right now?
Growth is slowing. In Q3 2026 it sold 6% less than a year earlier. The year before, quarters averaged 5%.
Since Oct 2026 the share price has fallen 21%, from $11.47 to $9.04.
Recently
August 5, 2026
Crop protection net sales, first half (Jan-Jun) changed to $3.7B
Corteva Q2 2026 results releaseAugust 5, 2026
Crop protection segment operating EBITDA margin, Q2 changed to 18.5%
Corteva Q2 2026 results releaseFebruary 5, 2026
Crop Protection net sales, full year changed to $7.5B
Corteva FY2025 10-K
Coming up
November 11–12, 2026
First quarterly results after the Seed spin-off
Corteva plans to release third-quarter results on November 11 and discuss them on November 12. The update may clarify how the crop protection business is performing on its own.
Corteva announces third-quarter earnings datesFourth quarter 2026
Planned Globachem venture
Corteva expects to close a joint venture to develop crop protection products with Globachem, subject to regulatory approvals.
Corteva and Globachem announce planned joint ventureFall 2027
Emiox fungicide launch
Corteva plans to launch a product for protecting golf greens from fungal diseases.
Corteva announces planned Emiox launch
Our own estimate moved too: the base case went from $19.01 to $14.66 a share between our last two valuations. The biggest reason: Crop Protection net sales, full year moved from an unreported prior value to $7.5B, as reported in Corteva FY2025 10-K.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Product approvals
Seed traits and crop protection products need government approval in each market. Delays, restrictions or lost approvals could prevent sales.
From the company's own filingsWould hit how fast sales growCorteva 2025 Form 10-K
New products may fall short
Developing new products takes years, and few ideas reach the market. Farmers may adopt a new product more slowly than Corteva expects.
From the company's own filingsWould hit how fast sales growCorteva 2025 Form 10-K
Weather and growing seasons
Planting delays and extreme weather can change demand and affect the amount, quality and cost of seed Corteva produces.
From the company's own filingsWould hit how fast sales growCorteva 2025 Form 10-K
Competitive prices
Rivals and lower-cost generic chemicals can put pressure on prices. Corteva reported competitive Crop Protection pricing in Latin America in 2025.
From the company's own filingsWould hit how much of each sale it keepsCorteva 2025 Form 10-K
Supply and input costs
Raw material shortages or higher production costs could reduce profits if Corteva cannot offset them. A material portion of its crop protection inputs comes directly or indirectly from China.
From the company's own filingsWould hit how much of each sale it keepsCorteva 2025 Form 10-K
Legacy environmental claims
Environmental cleanup and lawsuits tied to current and former businesses may cost more than Corteva has estimated.
From the company's own filingsWould hit how much it has to reinvestCorteva 2025 Form 10-K
Q3 2026 Crop Protection price was down 7% year over year.
From our researchWould hit how fast sales growCorteva Q3 2026 10-Q
Full-year 2026 Crop Protection EBITDA guidance fell to $1.1-1.125B from about $1.3B.
From our researchWould hit how much of each sale it keepsGuruFocus Q3 2026 call highlights
Is it a good business?
From 2018 to 2025 it earned between -7% and 7% on its shareholders' equity, a median of 3%.
It bought back shares: the count fell 1.6% in a year, so each remaining share owns a slightly bigger slice.
It owes $3.5B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $9.04. Our put its value between $5.58 and $26.34, with $14.66 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $5.58
After spinning off its seed business, Corteva keeps a crop-chemicals company whose sales slipped this year, and this scenario assumes cheap generic competition in Brazil keeps sales roughly flat and profits thinner for years.
Base case, $14.66
Now a pure crop-chemicals company after the seed spin-off, Corteva is assumed to get through this year's Brazil-driven dip and return to slow, steady growth, with profitability recovering toward the levels it reached in 2024 and 2025.
Bull case, $26.34
This scenario assumes the newly standalone crop-chemicals company quickly recovers from this year's Brazil slowdown and then grows a bit faster than in the past, as new products win farmers over and profits climb above their 2025 level.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects less than we do.Margin of safety: 38%
At today's $9.04, the price makes sense if sales shrink about 21.8% a year. We assume they shrink 9.2%. Over the last 5 years, sales grew 2.8% a year.
Or, if sales shrink 9.2% as we assume, the price works with a profit margin of 10.1% (we assume 14.0%).
Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.
Do you think sales will shrink about 21.8% a year?
Try your own numbersWe're moderately sure of this range: it scores 51 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $14.66 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average-9.2%
Next year -58.5%, then about 3%
- Operating margin14.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$14.66 62.1%


